Teladoc Earnings Calls
| Release date | Apr 29, 2026 |
| EPS estimate | -$0.341 |
| EPS actual | -$0.360 |
| EPS Surprise | -5.52% |
| Revenue estimate | 610.854M |
| Revenue actual | 613.845M |
| Revenue Surprise | 0.490% |
| Release date | Feb 25, 2026 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.140 |
| EPS Surprise | 26.32% |
| Revenue estimate | 635.312M |
| Revenue actual | 642.269M |
| Revenue Surprise | 1.10% |
| Release date | Oct 29, 2025 |
| EPS estimate | -$0.260 |
| EPS actual | -$0.210 |
| EPS Surprise | 19.23% |
| Revenue estimate | 635.329M |
| Revenue actual | 626.439M |
| Revenue Surprise | -1.40% |
| Release date | Jul 29, 2025 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.190 |
| EPS Surprise | 29.63% |
| Revenue estimate | 627.743M |
| Revenue actual | 631.9M |
| Revenue Surprise | 0.662% |
Last 4 Quarters for Teladoc
Below you can see how TDOC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 29, 2025 |
| Price on release | $7.53 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.190 |
| EPS surprise | 29.63% |
| Date | Price |
|---|---|
| Jul 23, 2025 | $8.58 |
| Jul 24, 2025 | $8.20 |
| Jul 25, 2025 | $8.20 |
| Jul 28, 2025 | $8.20 |
| Jul 29, 2025 | $7.53 |
| Jul 30, 2025 | $7.40 |
| Jul 31, 2025 | $7.21 |
| Aug 01, 2025 | $6.94 |
| Aug 04, 2025 | $6.97 |
| 4 days before | -12.24% |
| 4 days after | -7.44% |
| On release day | -1.73% |
| Change in period | -18.76% |
| Release date | Oct 29, 2025 |
| Price on release | $8.23 |
| EPS estimate | -$0.260 |
| EPS actual | -$0.210 |
| EPS surprise | 19.23% |
| Date | Price |
|---|---|
| Oct 23, 2025 | $8.60 |
| Oct 24, 2025 | $9.46 |
| Oct 27, 2025 | $9.01 |
| Oct 28, 2025 | $8.36 |
| Oct 29, 2025 | $8.23 |
| Oct 30, 2025 | $8.74 |
| Oct 31, 2025 | $8.63 |
| Nov 03, 2025 | $8.14 |
| Nov 04, 2025 | $7.98 |
| 4 days before | -4.30% |
| 4 days after | -3.04% |
| On release day | 6.20% |
| Change in period | -7.21% |
| Release date | Feb 25, 2026 |
| Price on release | $4.65 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.140 |
| EPS surprise | 26.32% |
| Date | Price |
|---|---|
| Feb 19, 2026 | $4.88 |
| Feb 20, 2026 | $4.74 |
| Feb 23, 2026 | $4.56 |
| Feb 24, 2026 | $4.54 |
| Feb 25, 2026 | $4.65 |
| Feb 26, 2026 | $5.35 |
| Feb 27, 2026 | $5.26 |
| Mar 02, 2026 | $5.16 |
| Mar 03, 2026 | $5.10 |
| 4 days before | -4.71% |
| 4 days after | 9.68% |
| On release day | 15.05% |
| Change in period | 4.51% |
| Release date | Apr 29, 2026 |
| Price on release | $5.95 |
| EPS estimate | -$0.341 |
| EPS actual | -$0.360 |
| EPS surprise | -5.52% |
| Date | Price |
|---|---|
| Apr 23, 2026 | $5.70 |
| Apr 24, 2026 | $5.75 |
| Apr 27, 2026 | $5.85 |
| Apr 28, 2026 | $6.00 |
| Apr 29, 2026 | $5.95 |
| Apr 30, 2026 | $6.06 |
| May 01, 2026 | $6.46 |
| May 04, 2026 | $6.63 |
| May 05, 2026 | $6.66 |
| 4 days before | 4.39% |
| 4 days after | 11.93% |
| On release day | 1.85% |
| Change in period | 16.84% |
Teladoc Earnings Call Transcript Summary of Q1 2026
Teladoc reported Q1 2026 consolidated revenue of $614M and adjusted EBITDA of $58M (9.5% margin), both above guidance midpoints. Cash was $751M and net debt to trailing adjusted EBITDA was <0.9x (3.6x on a gross debt basis). Integrated Care delivered $395M in revenue (up 1.5% YoY) with adjusted EBITDA of $56M (14.2% margin); strength came from visit revenue growth and international/hybrid care, while subscription revenue continued to decline as clients shift toward visit-based models. BetterHelp revenue was $218M (down 9% YoY) with adjusted EBITDA of $2M (0.9% margin); management attributes the weakness in direct-to-consumer cash pay to the broader consumer environment but is seeing meaningful early success scaling insurance coverage after the UpLift acquisition. BetterHelp is live in 30 states + DC, has credentialed >6,000 providers, insurance-contracted lives >150M, and insurance-covered sessions running >14,000/week (annualized run-rate >$75M) with an expected 2026 exit run-rate of at least $125M. Management is investing in AI and data infrastructure (Pulse and Prism) to improve care delivery and operational efficiency, including AI-assisted documentation that has saved therapists ~15 minutes/session. Company reiterated full-year 2026 guidance: revenue $2.48B–$2.58B, adjusted EBITDA $267M–$306M, free cash flow $130M–$170M; they expect SBP expense < $55M for the year. Strategic priorities include product innovation, scaling insurance for BetterHelp, margin improvement in Integrated Care (targeting ~15.1%–16.1% margin), and a two-phase plan to address the 2027 convertible notes to materially lower gross debt. Key near-term risks/notes for investors: continued mix shift from subscription to visits (near-term revenue mix headwinds, but expected to become a tailwind by H2), BetterHelp DTC softness (offsetting insurance growth), therapist capacity as a potential gating factor for insurance scale, and macro/payer enrollment dynamics (ACA/subsidy effects) that could moderate membership trends.
Sign In
Buy TDOC